Komodo Health vs Truveta

Verdict

Komodo Health and Truveta both provide de-identified, patient-level real-world data to life-sciences and research teams, but they source that data in structurally different ways. Komodo Health builds its Healthcare Map primarily from medical and pharmacy claims plus clinical data, used to model disease prevalence and treatment pathways and to support use cases like clinical-trial site selection and market sizing for pharma customers. Truveta is a data collaborative collectively owned by a group of major U.S. health systems, which contribute de-identified EHR data — including clinical notes, labs and imaging metadata — directly into a shared dataset accessed through Truveta Studio, using natural-language processing to structure the unstructured clinical notes. Because Truveta's data originates from the EHR itself rather than a billing event, it aims to capture clinical detail that claims-only data misses; Komodo's claims-centered approach in turn gives it breadth across care settings that a smaller group of contributing health systems may not fully cover.

Choose Komodo Health if

• Claims-based breadth across many care settings and payers matters more than depth of clinical narrative.
• You need patient-journey and treatment-pathway modeling for market sizing or clinical-trial site selection.
• You're a pharma or life-sciences commercial team, which is Komodo's primary customer base alongside payers and providers.

Choose Truveta if

• Clinical detail — notes, labs, imaging metadata — matters more than claims-level breadth for your research question.
• You're a researcher or life-sciences team studying disease progression, treatment effectiveness or safety signals that require reading unstructured clinical narrative.
• Knowing the data is sourced and governed directly by contributing health systems, rather than aggregated from claims intermediaries, matters to your data-provenance requirements.

The honest caveat

Both vendors de-identify data before use and operate under HIPAA's provisions for de-identified and research-use data, but "de-identified" is not the same as "unregulated" — confirm each vendor's specific de-identification methodology and data-use agreement terms before assuming interchangeability. Neither company publishes pricing; both license access to researchers and life-sciences organizations through negotiated agreements. See choosing a healthcare analytics platform for how IQVIA and Tempus AI round out the real-world-data landscape.